The role of complement in tumor growth

Advances in Experimental Medicine and Biology

Volumn 772, Issue , 2014, Pages 229-262

  Pio, Ruben ^a   Corrales, Leticia ^b   Lambris, John D ^c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anaphylatoxins; Angiogenesis; Cancer; Complement activation; Complement inhibitors; Immunosuppression; Immunotherapy; Monoclonal antibodies; Tumor microenvironment

Indexed keywords

COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C2A; COMPLEMENT COMPONENT C2B; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR H; DECAY ACCELERATING FACTOR; LECTIN; MONOCLONAL ANTIBODY;

ANAPHYLACTIC SHOCK; BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT SYSTEM; CONFERENCE PAPER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; CELL PROLIFERATION; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84934435141     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5915-6_11     Document Type: Conference Paper

References (257)

1. Abbott RJ, Spendlove I, Roversi P et al (2007) Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem 282(30): 22023-22032
2. Ajona D, Castano Z, Garayoa M et al (2004) Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 64(17):6310-6318
3. Ajona D, Hsu YF, Corrales L et al (2007) Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178(9):5991-5998
4. Albrecht EA, Chinnaiyan AM, Varambally S et al (2004) C5a-Induced gene expression in human umbilical vein endothelial cells. Am J Pathol 164(3):849-859
5. Amara U, Rittirsch D, Flierl M et al (2008) Interaction between the coagulation and complement system. Adv Exp Med Biol 632:71-79
6. Andoh A, Shimada M, Araki Y et al (2002) Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells. Cancer Immunol Immunother 50(12):663-672
7. Aspord C, Pedroza-Gonzalez A, Gallegos M et al (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204(5):1037-1047
8. Baatrup G, Qvist N, Junker A et al (1994) Activity and activation of the complement system in patients being operated on for cancer of the colon. Eur J Surg 160(9):503-510
9. Badea TC, Niculescu FI, Soane L et al (1998) Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem 273(41):26977-26981
10. Badea T, Niculescu F, Soane L et al (2002) RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem 277(1):502-508
11. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539-545
12. Bandyopadhyay M, Rohrer B (2012) Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement. Invest Ophthalmol Vis Sci 53(4):1953-1961
13. Battistelli S, Vittoria A, Cappelli R et al (2005) Protein S in cancer patients with non-metastatic solid tumours. Eur J Surg Oncol 31(7):798-802
14. Bauer S, Groh V, Wu J et al (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285(5428):727-729
15. Bellone S, Roque D, Cocco E et al (2012) Down regulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for Trastuzumab-based immunotherapy. Br J Cancer 106(9):1543-1550
16. Benard M, Gonzalez BJ, Schouft MT et al (2004) Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation. Neuroprotective effect of C5a against apoptotic cell death. J Biol Chem 279(42):43487-43496
17. Beum PV, Lindorfer MA, Beurskens F et al (2008) Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 181(1):822-832
18. Beurskens FJ, Lindorfer MA, Farooqui M et al (2012) Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 188(7):3532-3541
19. Bexborn F, Andersson PO, Chen H et al (2008) The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol 45(8):2370-2379
20. Bjorge L, Hakulinen J, Vintermyr OK et al (2005) Ascitic complement system in ovarian cancer. Br J Cancer 92(5):895-905
21. Blok VT, Gelderman KA, Tijsma OH et al (2003) Cytokines affect resistance of human renal tumour cells to complement-mediated injury. Scand J Immunol 57(6):591-599
22. Blom AM, Villoutreix BO, Dahlback B (2004) Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? Mol Immunol 40(18):1333-1346
23. Bohana-Kashtan O, Pinna LA, Fishelson Z (2005) Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis. Eur J Immunol 35(6):1939-1948
24. Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18(6):267-268
25. Bora PS, Sohn JH, Cruz JM et al (2005) Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol 174(1):491-497
26. Boulay F, Mery L, Tardif M et al (1991) Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 30(12):2993-2999
27. Brasoveanu LI, Altomonte M, Fonsatti E et al (1996) Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 74(1):33-42
28. Brasoveanu LI, Fonsatti E, Visintin A et al (1997) Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. J Clin Invest 100(5):1248-1255
29. Bu X, Zheng Z, Wang C et al (2007) Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells. Pathol Res Pract 203(3):163-167
30. Budzko DB, Lachmann PJ, McConnell I (1976) Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol 22(1):98-109
31. Buo L, Karlsrud TS, Dyrhaug G et al (1993) Differential diagnosis of human ascites: inhibitors of the contact system and total proteins. Scand J Gastroenterol 28(9):777-782
32. Cardarelli PM, Quinn M, Buckman D et al (2002) Binding to CD20 by anti-B1 antibody or F(ab') (2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 51(1):15-24
33. Carli M, Bucolo C, Pannunzio MT et al (1979) Fluctuation of serum complement levels in children with neuroblastoma. Cancer 43(6):2399-2404
34. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9(6):653-660
35. Carney DF, Lang TJ, Shin ML (1990) Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol 145(2):623-629
36. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559-1564
37. Chen S, Caragine T, Cheung NK et al (2000) CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neu-roblastoma. Cancer Res 60(11):3013-3018
38. Chen NJ, Mirtsos C, Suh D et al (2007) C5L2 Is critical for the biological activities of the ana-phylatoxins C5a and C3a. Nature 446(7132):203-207
39. Cheng ZZ, Corey MJ, Parepalo M et al (2005) Complement factor H as a marker for detection of bladder cancer. Clin Chem 51(5):856-863
40. Cole DS, Morgan BP (2003) Beyond lysis: how complement influences cell fate. Clin Sci (Lond) 104(5):455-466
41. Colotta F, Allavena P, Sica A et al (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073-1081
42. Coral S, Fonsatti E, Sigalotti L et al (2000) Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. J Cell Physiol 185(3):317-323
43. Corey MJ, Kinders RJ, Brown LG et al (1997) A very sensitive coupled luminescent assay for cytotoxicity and complement-mediated lysis. J Immunol Methods 207(1):43-51
44. Corrales L, Ajona D, Rafail S et al (2012) Anaphylatoxin c5a creates a favorable microenviron-ment for lung cancer progression. J Immunol 189(9):4674-4683
45. Costello LC, Franklin RB (2005) 'Why do tumour cells glycolyse?': from glycolysis through citrate to lipogenesis. Mol Cell Biochem 280(1-2):1-8
46. Cragg MS, Glennie MJ (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103(7):2738-2743
47. Cui T, Chen Y, Knosel T et al (2011) Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int J Oncol 39(1):161-168
48. Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942-949
49. Davis AE 3rd, Mejia P, Lu F (2008) Biological activities of C1 inhibitor. Mol Immunol 45(16):4057-4063
50. de Cordoba SR, de Jorge EG (2008) Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 151(1):1-13
51. Di Gaetano N, Xiao Y, Erba E et al (2001) Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114(4):800-809
52. Di Gaetano N, Cittera E, Nota R et al (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171(3):1581-1587
53. Donin N, Jurianz K, Ziporen L et al (2003) Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 131(2):254-263
54. Dunn GP, Old LJ, Schreiber RD (2004a) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360
55. Dunn GP, Old LJ, Schreiber RD (2004b) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137-148
56. DuPage M, Mazumdar C, Schmidt LM et al (2012) Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482(7385):405-409
57. Durrant LG, Chapman MA, Buckley DJ et al (2003) Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52(10):638-642
58. Elvington M, Huang Y, Morgan BP et al (2012) A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood 119(25):6043-6051
59. Falgarone G, Chiocchia G (2009) Chapter 8: clusterin: a multifacet protein at the crossroad of inflammation and autoimmunity. Adv Cancer Res 104:139-170
60. Fearon DT (1979) Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 76(11):5867-5871
61. Fearon DT, Carter RH (1995) The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 13:127-149
62. Fedarko NS, Fohr B, Robey PG et al (2000) Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 275(22):16666-16672
63. Fischer E, Appay MD, Cook J et al (1986) Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor. J Immunol 136(4):1373-1377
64. Fishelson Z, Donin N, Zell S et al (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40(2-4):109-123
65. Fosbrink M, Cudrici C, Niculescu F et al (2005) Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol 78(2):116-122
66. Frade R, Rodrigues-Lima F, Huang S et al (1998) Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res 58(13):2733-2736
67. Fridman WH, Pages F, Sautes-Fridman C et al (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298-306
68. Fust G, Miszlay Z, Czink E et al (1987) C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance. Immunol Lett 14(3):255-259
69. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162-174
70. Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960-1964
71. Gancz D, Fishelson Z (2009) Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development. Mol Immunol 46(14):2794-2800
72. Gao LJ, Guo SY, Cai YQ et al (2009) Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells. BMC Cancer 9:384
73. Gasque P, Thomas A, Fontaine M et al (1996) Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J Neuroimmunol 66(1-2):29-40
74. Geis N, Zell S, Rutz R et al (2010) Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets 10(8):922-931
75. Gelderman KA, Blok VT, Fleuren GJ et al (2002a) The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 82(4):483-493
76. Gelderman KA, Kuppen PJ, Bruin W et al (2002b) Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur J Immunol 32(1):128-135
77. Gelderman KA, Kuppen PJ, Okada N et al (2004a) Tumor-specific inhibition of membrane-bound complement regulatory protein crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res 64(12):4366-4372
78. Gelderman KA, Tomlinson S, Ross GD et al (2004b) Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25(3):158-164
79. Gelderman KA, Lam S, Gorter A (2005) Inhibiting complement regulators in cancer immuno-therapy with bispecific mAbs. Expert Opin Biol Ther 5(12):1593-1601
80. Ghiran I, Barbashov SF, Klickstein LB et al (2000) Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med 192(12):1797-1808
81. Girardi G, Yarilin D, Thurman JM et al (2006) Complement activation induces dysregulation of angio-genic factors and causes fetal rejection and growth restriction. J Exp Med 203(9):2165-2175
82. Glunde K, Serkova NJ (2006) Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7(7):1109-1123
83. Gminski J, Mykala-Ciesla J, Machalski M et al (1992) Immunoglobulins and complement components levels in patients with lung cancer. Rom J Intern Med 30(1):39-44
84. Golay J, Zaffaroni L, Vaccari T et al (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95(12):3900-3908
85. Gonzalez JM, Franzke CW, Yang F et al (2011) Complement activation triggers metalloprotein-ases release inducing cervical remodeling and preterm birth in mice. Am J Pathol 179(2):838-849
86. Gorter A, Meri S (1999) Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 20(12):576-582
87. Governa M, Fenoglio I, Amati M et al (2002) Cleavage of the fifth component of human complement and release of a split product with C5a-like activity by crystalline silica through free radical generation and kallikrein activation. Toxicol Appl Pharmacol 179(3):129-136
88. Griffin JL, Kauppinen RA (2007) Tumour metabolomics in animal models of human cancer. J Proteome Res 6(2):498-505
89. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883-899
90. Guidi L, Baroni R, Bartoloni C et al (1988) Immune complexes in solid tumours precipitable by 3.5% Polyethylene glycol: analysis of some nonspecific components. Diagn Clin Immunol 5(6):284-288
91. Gunn L, Ding C, Liu M et al (2012) Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 189(6):2985-2994
92. Haas PJ, van Strijp J (2007) Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res 37(3):161-175
93. Hakomori S (2002) Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 99(16):10231-10233
94. Hakulinen J, Junnikkala S, Sorsa T et al (2004) Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol 34(9):2620-2629
95. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674
96. Hawrylowicz CM, O'Garra A (2005) Potential role of interleukin-10- secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 5(4):271-283
97. He JQ, Wiesmann C, van Lookeren CM (2008) A role of macrophage complement receptor CRIg in immune clearance and inflammation. Mol Immunol 45(16):4041-4047
98. Helmy K Y, Katschke KJ Jr, Gorgani NN et al (2006) CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124(5):915-927
99. Hindmarsh EJ, Marks RM (1998) Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur J Immunol 28(3):1052-1062
100. Holliger P, Wing M, Pound JD et al (1997) Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol 15(7):632-636
101. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4(1):45-60
102. Holmberg MT, Blom AM, Meri S (2001) Regulation of complement classical pathway by association of C4b-binding protein to the surfaces of SK-OV-3 and caov-3 ovarian adenocarcinoma cells. J Immunol 167(2):935-939
103. Hourcade DE (2008) Properdin and complement activation: a fresh perspective. Curr Drug Targets 9(2):158-164
104. Hsu YF, Ajona D, Corrales L et al (2010) Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol Cancer 9:139
105. Huber-Lang M, Younkin EM, Sarma JV et al (2002) Generation of C5a by phagocytic cells. Am J Pathol 161(5):1849-1859
106. Huber-Lang M, Sarma JV, Zetoune FS et al (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12(6):682-687
107. Jain A, Karadag A, Fohr B et al (2002) Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 277(16):13700-13708
108. Jarvis GA, Li J, Hakulinen J et al (1997) Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 71(6):1049-1055
109. Jenne DE, Tschopp J (1989) Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycopro-tein 2, a constituent of rat testis fluid. Proc Natl Acad Sci USA 86(18):7123-7127
110. Jiang H, Cooper B, Robey FA et al (1992) DNA binds and activates complement via residues 14-26 of the human C1q a chain. J Biol Chem 267(35):25597-25601
111. Jozsi M, Zipfel PF (2008) Factor H family proteins and human diseases. Trends Immunol 29(8):380-387
112. Juhl H, Petrella EC, Cheung NK et al (1990) Complement killing of human Neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic. Mol Immunol 27(10):957-964
113. Juhl H, Sievers M, Baltzer K et al (1995) A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach. Cancer Res 55(23 Suppl):5749s-5755s
114. Juhl H, Petrella EC, Cheung NK et al (1997) Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human Neuroblastoma cells. Immunobiology 197(5):444-459
115. Junnikkala S, Jokiranta TS, Friese MA et al (2000) Exceptional resistance of human H2 glioblas-toma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 164(11):6075-6081
116. Junnikkala S, Hakulinen J, Jarva H et al (2002) Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 87(10):1119-1127
117. Jurianz K, Ziegler S, Garcia-Schuler H et al (1999) Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36(13-14):929-939
118. Jurianz K, Ziegler S, Donin N et al (2001) K562 Erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int J Cancer 93(6):848-854
119. Kalwinsky DK, Urmson JR, Stitzel AE et al (1976) Activation of the alternative pathway of complement in childhood acute lymphoblastic leukemia. J Lab Clin Med 88(5):745-756
120. Karre K, Ljunggren HG, Piontek G et al (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319(6055):675-678
121. Kataki A, Scheid P, Piet M et al (2002) Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 140(5):320-328
122. Kawada M, Mizuno M, Nasu J et al (2003) Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. J Lab Clin Med 142(5):306-312
123. Kemper C, Chan AC, Green JM et al (2003) Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421(6921):388-392
124. Kennedy AD, Solga MD, Schuman TA et al (2003) An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101(3):1071-1079
125. Kim SH, Carney DF, Hammer CH et al (1987) Nucleated cell killing by complement: effects of C5b-9 channel size and extracellular Ca2+ on the lytic process. J Immunol 138(5):1530-1536
126. Kim R, Emi M, Tanabe K et al (2006) Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66(11):5527-5536
127. Kimberley FC, Sivasankar B, Paul Morgan B (2007) Alternative roles for CD59. Mol Immunol 44(1-3):73-81
128. Kinders R, Jones T, Root R et al (1998) Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 4(10):2511-2520
129. Kirkitadze MD, Barlow PN (2001) Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev 180:146-161
130. Klickstein LB, Barbashov SF, Liu T et al (1997) Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 7(3):345-355
131. Kohl J (2001) Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 38(2-3):175-187
132. Kohno H, Mizuno M, Nasu J et al (2005) Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis. J Gastroenterol Hepatol 20(1):73-78
133. Kojouharova M, Reid K, Gadjeva M (2010) New insights into the molecular mechanisms of classical complement activation. Mol Immunol 47(13):2154-2160
134. Kolev M, Towner L, Donev R (2011) Complement in cancer and cancer immunotherapy. Arch Immunol Ther Exp (Warsz) 59(6):407-419
135. Kraus S, Seger R, Fishelson Z (2001) Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis. Clin Exp Immunol 123(3):366-374
136. Kraut EH, Sagone AL Jr (1981) Alternative pathway of complement in multiple myeloma. Am J Hematol 11(4):335-345
137. Krych-Goldberg M, Atkinson JP (2001) Structure-function relationships of complement receptor type 1. Immunol Rev 180:112-122
138. Laghi L, Bianchi P, Miranda E et al (2009) CD3+ Cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 10(9):877-884
139. Langer HF, Chung KJ, Orlova VV et al (2010) Complement-mediated inhibition of neovascular-ization reveals a point of convergence between innate immunity and angiogenesis. Blood 116(22):4395-4403
140. Law SK, Dodds AW (1997) The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 6(2):263-274
141. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66(2):605-612
142. Li L, Spendlove I, Morgan J et al (2001) CD55 is over-expressed in the tumour environment. Br J Cancer 84(1):80-86
143. Liszewski MK, Post TW, Atkinson JP (1991) Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 9:431-455
144. Liu J, Miwa T, Hilliard B et al (2005) The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201(4):567-577
145. Liu L, Li W, Li Z et al (2012) Sublytic complement protects prostate cancer cells from tumour necrosis factor-alpha-induced cell death. Clin Exp Immunol 169(2):100-108
146. Livingston PO, Hood C, Krug LM et al (2005) Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol Immunother 54(10):1018-1025
147. Loberg RD, Wojno KJ, Day LL et al (2005) Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology 66(6):1321-1326
148. Lublin DM, Atkinson JP (1989) Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 7:35-58
149. Lucas SD, Karlsson-Parra A, Nilsson B et al (1996) Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 27(12):1329-1335
150. Macor P, Tedesco F (2007) Complement as effector system in cancer immunotherapy. Immunol Lett 111(1):6-13
151. Macor P, Mezzanzanica D, Cossetti C et al (2006) Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res 66(7):3876-3883
152. Madjd Z, Durrant LG, Bradley R et al (2004) Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res 10(8):2797-2803
153. Madjd Z, Durrant LG, Pinder SE et al (2005) Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)? Cancer Immunol Immunother 54(2):149-156
154. Maness PF, Orengo A (1977) Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases. Oncology 34(2):87-89
155. Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454(7203):436-444
156. Marie JC, Astier AL, Rivailler P et al (2002) Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol 3(7):659-666
157. Markiewski MM, Nilsson B, Ekdahl KN et al (2007) Complement and coagulation: strangers or partners in crime? Trends Immunol 28(4):184-192
158. Markiewski MM, DeAngelis RA, Benencia F et al (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9(11):1225-1235
159. Markiewski MM, DeAngelis RA, Strey CW et al (2009) The regulation of liver cell survival by complement. J Immunol 182(9):5412-5418
160. Matsushita M, Thiel S, Jensenius JC et al (2000) Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol 165(5):2637-2642
161. Matsushita H, Vesely MD, Koboldt DC et al (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385):400-404
162. Matsutani M, Suzuki T, Hori T et al (1984) Cellular immunity and complement levels in hosts with brain tumours. Neurosurg Rev 7(1):29-35
163. McConnell I, Klein G, Lint TF et al (1978) Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur J Immunol 8(7):453-458
164. McGrath FD, Brouwer MC, Arlaud GJ et al (2006) Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J Immunol 176(5):2950-2957
165. McMullen ME, Hart ML, Walsh MC et al (2006) Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology 211(10):759-766
166. Medof ME, Walter EI, Rutgers JL et al (1987) Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 165(3):848-864
167. Meri S, Morgan BP, Davies A et al (1990) Human protectin (CD59), an 18, 000-20, 000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71(1):1-9
168. Michlmayr A, Bachleitner-Hofmann T, Baumann S et al (2011) Modulation of plasma complement by the initial dose of Epirubicin/docetaxel therapy in breast cancer and its predictive value. Br J Cancer 103(8):1201-1208
169. Mitchell DA, Kirby L, Paulin SM et al (2007) Prion protein activates and fixes complement directly via the classical pathway: implications for the mechanism of scrapie agent propagation in lym-phoid tissue. Mol Immunol 44(11):2997-3004
170. Miyagi T, Takahashi K, Moriya S et al (2012) Altered expression of sialidases in human cancer. Adv Exp Med Biol 749:257-267
171. Montuenga LM, Pio R (2007) Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. Eur Respir J 30(4):608-610
172. Moore GL, Chen H, Karki S et al (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2(2):181-189
173. Morgan BP (1989) Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 264(1):1-14
174. Morgan BP (1992) Effects of the membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol 178:115-140
175. Morgan BP (1999) Regulation of the complement membrane attack pathway. Crit Rev Immunol 19(3):173-198
176. Morgan J, Spendlove I, Durrant LG (2002) The role of CD55 in protecting the tumour environment from complement attack. Tissue Antigens 60(3):213-223
177. Morris KM, Aden DP, Knowles BB et al (1982) Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest 70(4):906-913
178. Moskovich O, Fishelson Z (2007) Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex. J Biol Chem 282(41):29977-29986
179. Mukherjee P, Pasinetti GM (2001) Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J Neurochem 77(1):43-49
180. Mukherjee P, Thomas S, Pasinetti GM (2008) Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J Neuroinflammation 5:5
181. Mustafa T, Klonisch T, Hombach-Klonisch S et al (2004) Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol 24(2):285-294
182. Nagajothi N, Matsui WH, Mukhina GL et al (2004) Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins. Leuk Lymphoma 45(4):795-799
183. Nasu J, Mizuno M, Uesu T et al (1998) Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol 113(3):379-385
184. Nauta AJ, Trouw LA, Daha MR et al (2002) Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 32(6):1726-1736
185. Niculescu F, Rus HG, Retegan M et al (1992) Persistent complement activation on tumor cells in breast cancer. Am J Pathol 140(5):1039-1043
186. Niculescu F, Rus H, van Biesen T et al (1997) Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J Immunol 158(9):4405-4412
187. Niculescu F, Badea T, Rus H (1999) Sublytic C5b-9 induces proliferation
188. Niehans GA, Cherwitz DL, Staley NA et al (1996) Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149(1):129-142
189. Nishioka K, Kawamura K, Hirayama T et al (1976) The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann N Y Acad Sci 276:303-315
190. Nolte-'t Hoen EN, Almeida CR, Cohen NR et al (2007) Increased surveillance of cells in mitosis by human NK cells suggests a novel strategy for limiting tumor growth and viral replication. Blood 109(2):670-673
191. Nozaki M, Raisler BJ, Sakurai E et al (2006) Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 103(7):2328-2333
192. Nunez-Cruz S, Gimotty PA, Guerra MW et al (2012) Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14(11):994-1004
193. Ohno M, Hirata T, Enomoto M et al (2000) A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol 37(8):407-412
194. Okroj M, Hsu YF, Ajona D et al (2008) Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 45(1):169-179
195. Okroj M, Corrales L, Stokowska A et al (2009) Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol Immunother 58(11):1771-1780
196. Ollert MW, Frade R, Fiandino A et al (1990) C3-Cleaving membrane proteinase. A new complement regulatory protein of human melanoma cells. J Immunol 144(10):3862-3867
197. Ollert MW, David K, Bredehorst R et al (1995) Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b. J Immunol 155(10):4955-4962
198. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182(8):4499-4506
199. Paas Y, Bohana-Kashtan O, Fishelson Z (1999) Phosphorylation of the complement component, C9, by an ecto-protein kinase of human leukemic cells. Immunopharmacology 42(1-3):175-185
200. Pangburn MK, Rawal N (2002) Structure and function of complement C5 convertase enzymes. Biochem Soc Trans 30(Pt 6):1006-1010
201. Pangburn MK, Schreiber RD, Muller-Eberhard HJ (1981) Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 154(3):856-867
202. Pardoll D (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807-839
203. Peterson AC, Harlin H, Gajewski TF (2003) Immunization with melan-a peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21(12):2342-2348
204. Podack ER, Muller-Eberhard HJ (1979) Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem 254(19):9808-9814
205. Quatromoni JG, Eruslanov E (2012) Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 4(4):376-389
206. Ragupathi G, Liu NX, Musselli C et al (2005) Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 174(9):5706-5712
207. Reiter Y, Fishelson Z (1989) Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. J Immunol 142(8):2771-2777
208. Ricklin D, Hajishengallis G, Yang K et al (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11(9):785-797
209. Roberts SJ, Ng B Y, Filler RB et al (2007) Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci USA 104(16):6770-6775
210. Rozanov DV, Savinov AY, Golubkov VS et al (2006) Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res 66(12):6258-6263
211. Rushmere NK, Knowlden JM, Gee JM et al (2004) Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 108(6):930-936
212. Rutkowski MJ, Sughrue ME, Kane AJ et al (2010a) Cancer and the complement cascade. Mol Cancer Res 8(11):1453-1465
213. Rutkowski MJ, Sughrue ME, Kane AJ et al (2010b) The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res 59(11):897-905
214. Sadallah S, Lach E, Schwarz S et al (1999) Soluble complement receptor 1 is increased in patients with leukemia and after administration of granulocyte colony-stimulating factor. J Leukoc Biol 65(1):94-101
215. Schlesinger M, Broman I, Lugassy G (1996) The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 10(9):1509-1513
216. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5(2):147-159
217. Schraufstatter IU, Trieu K, Sikora L et al (2002) Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 169(4):2102-2110
218. Schraufstatter IU, Discipio RG, Zhao M et al (2009) C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol 182(6):3827-3836
219. Schuster M, Umana P, Ferrara C et al (2005) Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 65(17):7934-7941
220. Selander B, Martensson U, Weintraub A et al (2006) Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest 116(5):1425-1434
221. Seya T, Hara T, Iwata K et al (1995) Purification and functional properties of soluble forms of membrane cofactor protein (CD46) of complement: identification of forms increased in cancer patients' sera. Int Immunol 7(5):727-736
222. Shaw PX, Zhang L, Zhang M et al (2012) Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids. Proc Natl Acad Sci USA 109(34):13757-13762
223. Shi XX, Zhang B, Zang JL et al (2009) CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer. Cell Mol Immunol 6(1):61-66
224. Shimizu K, Nakata M, Hirami Y et al (2010) Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 5(5):585-590
225. Sim RB, Day AJ, Moffatt BE et al (1993) Complement factor I and cofactors in control of complement system convertase enzymes. Methods Enzymol 223:13-35
226. Sjoberg AP, Manderson GA, Morgelin M et al (2009) Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol 46(5):830-839
227. Soane L, Cho HJ, Niculescu F et al (2001) C5b-9 Terminal complement complex protects oligo-dendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol 167(4):2305-2311
228. Spiridon CI, Ghetie MA, Uhr J et al (2002) Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8(6):1720-1730
229. Strey CW, Markiewski M, Mastellos D et al (2003) The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 198(6):913-923
230. Tang Z, Lu B, Hatch E et al (2009) C3a Mediates epithelial-to-mesenchymal transition in protein-uric nephropathy. J Am Soc Nephrol 20(3):593-603
231. Taylor RP, Ferguson PJ, Martin EN et al (1997) Immune complexes bound to the primate erythro-cyte complement receptor (CR1) via anti-CR1 mAbs are cleared simultaneously with loss of CR1 in a concerted reaction in a rhesus monkey model. Clin Immunol Immunopathol 82(1):49-59
232. Tegla CA, Cudrici C, Patel S et al (2011) Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res 51(1):45-60
233. Terui Y, Sakurai T, Mishima Y et al (2006) Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci 97(1):72-79
234. Theofilopoulos AN, Perrin LH (1976) Binding of components of the properdin system to cultured human lymphoblastoid cells and B lymphocytes. J Exp Med 143(2):271-289
235. Thiel S (2007) Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol 44(16):3875-3888
236. Thornton AM, Shevach EM (1998) CD4+CD25+ Immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188(2):287-296
237. Trougakos IP, Gonos ES (2002) Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 34(11):1430-1448
238. Umansky V, Sevko A (2013) Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron 6(2):169-177
239. van Lookeren CM, Wiesmann C, Brown EJ (2007) Macrophage complement receptors and pathogen clearance. Cell Microbiol 9(9):2095-2102
240. Varga L, Czink E, Miszlai Z et al (1995) Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia. Clin Exp Immunol 99(1):112-116
241. Varsano S, Frolkis I, Rashkovsky L et al (1996) Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation. Am J Respir Cell Mol Biol 15(6):731-737
242. Varsano S, Rashkovsky L, Shapiro H et al (1998) Human lung cancer cell lines express cell membrane complement Inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 113(2):173-182
243. Vlaicu SI, Tegla CA, Cudrici CD et al (2013) Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer. Immunol Res 56(1):109-121
244. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344(14):1058-1066
245. Watson NF, Durrant LG, Madjd Z et al (2006) Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol Immunother 55(8):973-980
246. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5):317-327
247. Xu C, Jung M, Burkhardt M et al (2005) Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 62(3):224-232
248. Yamakawa M, Yamada K, Tsuge T et al (1994) Protection of thyroid cancer cells by complement-regulatory factors. Cancer 73(11):2808-2817
249. Yan J, Allendorf DJ, Li B et al (2008) The role of membrane complement regulatory proteins in cancer immunotherapy. Adv Exp Med Biol 632:159-174
250. Yefenof E, Zehavi-Feferman R, Guy R (1990) Control of primary and secondary antibody responses by cytotoxic T lymphocytes specific for a soluble antigen. Eur J Immunol 20(8):1849-1853
251. Ying SC, Gewurz AT, Jiang H et al (1993) Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the a chain collagen-like region of C1q. J Immunol 150(1):169-176
252. Ytting H, Jensenius JC, Christensen IJ et al (2004) Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J Gastroenterol 39(7):674-679
253. Ytting H, Christensen IJ, Thiel S et al (2005) Serum mannan-binding lectin-associated serine protease 2 levels in colorectal cancer: relation to recurrence and mortality. Clin Cancer Res 11(4):1441-1446
254. Zhang M, Takahashi K, Alicot EM et al (2006) Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J Immunol 177(7):4727-4734
255. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5(4):263-274
256. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6(4):295-307
257. Zurlo JJ, Schechter GP, Fries LF (1989) Complement abnormalities in multiple myeloma. Am J Med 87(4):411-420